BofA update shows where active managers are putting money
Investing.com - H.C. Wainwright has reduced its price target on United Therapeutics Corp . (NASDAQ:UTHR) to $400 from $425 while maintaining a Buy rating on the stock. The company, which boasts impressive gross margins of 89% and a perfect Piotroski Score of 9 according to InvestingPro data, has seen its shares decline nearly 8% over the past week.
The firm cited increased competition for United Therapeutics’ Tyvaso treatment as the primary reason for the adjustment, specifically pointing to the recent approval of Yutrepia, which is expected to decrease Tyvaso’s market penetration in both PAH and PH-ILD indications. Despite these concerns, the stock appears undervalued, trading at an attractive P/E ratio of 11.6 and near its 52-week low. Unlock 10+ additional valuable insights about UTHR with InvestingPro.
H.C. Wainwright noted that top-line data from the TETON 2 trial is expected in September, while results from the TETON 1 trial are anticipated in the first half of 2026.
The TETON trials are evaluating the use of nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF), a program that emerged from findings in the earlier INCREASE trial of nebulized Tyvaso for the treatment of PH-ILD.
Despite the reduced price target, H.C. Wainwright reiterated its Buy rating on United Therapeutics stock, suggesting continued confidence in the company’s overall prospects.
In other recent news, United Therapeutics Corporation released its second-quarter earnings for 2025, which did not meet analyst expectations. The company reported an earnings per share (EPS) of $6.41, which was lower than the anticipated $7.35. Additionally, United Therapeutics recorded revenue of $799 million, missing the forecasted $804.98 million. These results indicate a slight shortfall in both earnings and revenue targets. The announcement of these figures has been a focal point for investors assessing the company’s financial performance. Despite the shortfall, United Therapeutics continues to be closely monitored by analysts and investors alike. The earnings miss has sparked discussions about the company’s future strategies and performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.